WhiteOak Capital Pharma and Healthcare Fund Regular Growth
NAV ₹17.587 on 13 November 2026
AMFI name: WhiteOak Capital Pharma and Heathcare Fund Regular Plan Growth · Scheme code 152348 · ISIN INF03VN01878
Returns
To 13 November 2026. Up to 1 year: total change. 3 and 5 years: compound return a year.
| Period | This fund | NIFTY HEALTHCARE INDEX TRI | Category median |
|---|---|---|---|
| 1M | +10.21% | +8.67% | +8.25% |
| 6M | +17.14% | +12.84% | +9.28% |
| 1Y | +24.19% | +38.92% | +4.48% |
| 3Y | - | +28.05% | +15.37% |
| 5Y | - | - | +13.85% |
Benchmark: NIFTY HEALTHCARE INDEX TRI (total return index), measured over the same dates.
Category median: the middle return among Regular plans (Growth option) in AMFI's “Equity Schemes - Sectoral Fund” category, up to 20 funds with clean data. Ranks are under “Rank among peers”.
Risk
From daily NAVs. Alpha, beta and capture are measured against NIFTY HEALTHCARE INDEX TRI.
- Volatility
- 14.04%
- Annualised, 1 year
- Max drawdown
- -15.62%
- Worst fall from a peak, 3 years
- Sharpe ratio
- 1.30
- Return above the risk-free rate per unit of volatility, 1 year
- Sortino ratio
- 1.49
- Like Sharpe, counting only falls, 3 years
- Alpha
- +6.74%
- Return a year beyond what beta explains, 3 years
- Beta
- 0.55
- 1.00 moves in step with the benchmark, 3 years
- Upside capture
- 62%
- Share of the benchmark's rises captured, 3 years
- Downside capture
- 93%
- Share of the benchmark's falls taken (lower is better), 3 years
Rank among peers
Regular plans, Growth option, in AMFI's “Equity Schemes - Sectoral Fund” category. Each rank counts only the peers that have that figure.
| Rank | Scheme Name | 3Y Return | 1Y Return | Sharpe | Direct TER | AUM |
|---|---|---|---|---|---|---|
| #1 | Nippon India Mutual Fund | +46.52% | +60.64% | 1.07 | 1.06% | ₹1,100 Cr |
| #2 | HDFC Mutual Fund | +33.64% | +20.34% | 1.07 | 0.89% | ₹11,128 Cr |
| #3 | HDFC Mutual Fund | +31.28% | +31.60% | 1.76 | 1.03% | ₹3,128 Cr |
| #4 | SBI Mutual Fund | +25.42% | +26.07% | 1.47 | 0.76% | ₹5,565 Cr |
| #5 | HDFC Mutual Fund | +24.77% | +10.10% | 1.09 | 1.10% | ₹1,997 Cr |
| #6 | Mirae Asset Mutual Fund | +24.42% | +27.89% | 1.28 | - | ₹3,458 Cr |
| #7 | UTI Mutual Fund | +23.89% | +22.00% | 1.31 | 1.35% | ₹1,399 Cr |
| #8 | ICICI Prudential Mutual Fund | +22.73% | +10.29% | 0.95 | 2.08% | ₹3,926 Cr |
| #- | WhiteOak Capital Pharma and Healthcare FundCurrent Fund WhiteOak Capital Mutual Fund | - | +24.19% | 1.30 | 1.07% | ₹858 Cr |
Costs and fund facts
- Expense ratio (stated maximum)
- Direct 1.07% · Regular 2.74%
- Exit load
- Nil
- Fund size (all plans)
- ₹858 CrAverage, quarter to September 2026
- Benchmark
- NIFTY HEALTHCARE INDEX TRI
- Allotment date
- 6 February 2024Scheme document
- Type
- An open ended equity scheme investing in Pharma and Healthcare sector.
- AMFI scheme code
- 152348
Fund managers (5)
- Ramesh Mantrisince 06-Feb-2024
- Piyush Baranwalsince 06-Feb-2024
- Dheeresh Pathaksince 06-Feb-2024
- Ashish Agrawalsince 06-Jan-2025
- Trupti Agrawalsince 20-May-2025
How each manager has done since taking over: fund manager scorecard.
Investment objective
To provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved.
From the scheme summary document filed with AMFI.
SIP calculator
A monthly SIP replayed on this fund's actual daily NAVs: what it would be worth today.
About this fund
WhiteOak Capital Pharma and Healthcare Fund Regular Growth is a mutual fund scheme from WhiteOak Capital Mutual Fund, listed by AMFI under “Equity Schemes - Sectoral Fund”. This page covers the Regular plan with the Growth option. Its NAV was ₹17.587 on 13 November 2026. It returned 24.19% over 1 year, measured from NAVs (3- and 5-year figures are annualised). Its benchmark, NIFTY HEALTHCARE INDEX TRI, returned 38.92% over 1 year. Q-Score: 66 out of 100, rated only against funds in the same category. The fund house rates its risk as “Very High Risk” on the SEBI riskometer. Its average assets under management were ₹858 Cr across all plans for the quarter ending September 2026, as reported to AMFI. Its scheme summary document states a maximum expense ratio (TER) of 2.74% a year for the Regular plan. Managed by Ramesh Mantri, Piyush Baranwal, Dheeresh Pathak, Ashish Agrawal and Trupti Agrawal. Its scheme summary document gives the allotment date as 6 February 2024.
Figures are calculated from AMFI NAVs and index data, not taken from fund factsheets. Methodology. Past performance is not a guide to future returns.
Plans and options of this fund (2)
| Plan | Option | ISIN | AMFI code | NAV |
|---|---|---|---|---|
| RegularThis page | Growth | INF03VN01878 | 152348 | ₹17.5913 Nov 2026 |
| Direct | Growth | INF03VN01886 | 152349 | ₹18.4613 Nov 2026 |